HWPC(SH:688799) Chang Sha Wan Bao·2025-03-31 23:11Core Viewpoint - Warner Pharmaceutical's new project for producing 3,000 tons of high-end active pharmaceutical ingredients (APIs) and intermediates is progressing well, with trial production expected in the first half of next year, significantly enhancing Changsha's pharmaceutical manufacturing capacity [1][3][4] Group 1: Project Development - The construction of the Warner high-end API project has been underway for five months, with equipment installation expected to be completed this year and trial production starting in the first half of next year [1][3] - The project covers over 230 acres and includes more than 20 buildings, including 10 large workshops, with five workshops set to be topped out by May [3][6] - The project aims to produce products like sodium comfort and ticagrelor, with an expected annual output of 3,000 tons of high-end APIs and intermediates, contributing to a billion-level biopharmaceutical industry cluster in the region [3][4][6] Group 2: Employment and Training - The project is expected to create over 200 technical jobs, with recruitment and training already in progress [5][7] - Currently, 16 key personnel have been trained at relevant research centers, with ongoing recruitment efforts for additional technical workers [7] Group 3: Industry Positioning and Standards - The Warner high-end API project is positioned to become a leader in Changsha's API and excipient industry, following the company's previous successful investment in chiral drugs [4][6] - The project emphasizes international standards, aiming to align with global regulatory bodies such as the FDA, EMA, and PMDA, enhancing the company's international market share [9]